Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS

Share on StockTwits

Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 444 (CSE: DOSE) (OTC: MJNA) (OTCQB: AXIM) (CSE: XCX)


Delta, Kelowna, BC - July 21, 2020 ( Newswire), a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 444 (CSE: DOSE) (OTC: MJNA) (OTCQB: AXIM) (CSE: XCX)


Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

Today's podcast overview/transcript:

Good afternoon and welcome to another episode of "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today's podcast we look at a few public and private company announcements.

Rapid Dose Therapeutics Corp. (CSE: DOSE), a Canadian Life Sciences company focused on innovative drug and active ingredient delivery solutions, announced that it has begun COVID-19 vaccine research in conjunction with McMaster University and the team lead by Drs. Alex Adronov, James Mahony, and Mark Larche. The federally-funded project tests the use of QuickStrip™ for administering vaccines orally as a convenient and safe alternative to injection with needles, the currently accepted delivery format for most vaccines.

Dr. Adronov is a recognized Canadian expert in synthetic polymer chemistry and the development of novel polymer architectures, Dr. Mahony has extensive experience in virology and vaccine development, and Dr. Larche is an immunologist with expertise in vaccine research geared toward treatment of common allergies. The combined expertise of this research team will enable development and evaluation of oral vaccine delivery strategies.

Jason Lewis, RDT SVP said "RDT is focused on novel research through collaboration with the experts at McMaster. We see QuickStrip™, oral mucosa thin film delivery, as an efficient solution for distributing vaccines globally. Experts believe that antigens to COVID and other viruses can be delivered sublingually, a much easier and less expensive process than the current single or multidose vial methods. Imagine the significance of creating a vaccine that can be sent in an envelope, by mail."

"Our combined experience indicates that this is very feasible" said Dr. Adronov a recognized polymer expert leading the research project. "Our past collaborations with RDT in developing polymeric delivery innovations have resulted in solutions we are proud of, and continue to be involved with. Globally, we are seeing the development of many vaccines that we believe can be applied using sublingual delivery. Our project focuses on producing a polymer strip that delivers viral antigens by a transmucosal approach rather than injection. This funding will allow us to quickly get started, and we expect to generate positive results in the near future."

Mark Upsdell, RDT CEO, said "The current COVID situation requires everyone to think outside of the box as to how we might deliver safe, effective and timely solutions for combating COVID-19 and other viruses that require serum-based defenses. RDT remains committed to its research and innovation strategy which is highlighted now by our work on the COVID-19 project's unique delivery format. RDT provides scale-up testing and bench strength support for the McMaster research team in the race to provide an effective product that can be produced and delivered on a world-wide scale. A successful outcome of this project and its application with our QuickStrip™ delivery system will create exciting new opportunities for RDT."

Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company AXIM® Biotechnologies, Inc. (OTCQB: AXIM) has announced the development of a rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 (COVID-19) from infection.

Medical Marijuana, Inc. CEO Dr. Stuart Titus commented: "Our portfolio is proud to see the innovation that AXIM has showcased over the past few months and we are optimistic that this test could help make a difference in achieving our end-goal of overcoming this virus. Personally, I think that this kind of ingenuity will set us apart from our competitors and allow us to continue to grow the other facets of our business."

Unlike currently available COVID-19 tests that detect an antibody response to the virus, AXIM's rapid 10-minute test measures a specific subpopulation of antibodies to block the virus from attacking a person's body. While there are expensive, time-consuming laboratory tests that measure neutralizing antibodies, this test could be offered with easier convenience, lower cost and much faster -- results in 10 minutes -- than any other test on the market.

AXIM's test could also help ensure that vaccines elicit high levels of neutralizing antibodies. When a vaccine is available, manufacturers can employ this test to evaluate its effectiveness in vaccine recipients.

"We have succeeded at creating a test that is cost-efficient, accurate and fast - hopefully serving as an 'Immunity Passport™' for vaccine developers as they begin larger Phase II and III clinical trials," AXIM® Biotech CEO John W. Huemoeller II said.

AXIM has filed a Pre-Emergency Use Authorization and is compiling the necessary data from numerous tests recently completed that are needed to apply for an EUA from the FDA. AXIM makes clear that while the Company intends to file an EUA with the U.S. FDA, the U.S. FDA has not yet approved the Company's diagnostic test and there is no guarantee that any EUA once filed will be approved.

AMP German Cannabis Group Inc. (CSE: XCX) announced that it has placed two orders for bulk and finished EU-GMP medical cannabis flower from a Canadian Licensed Producer of medical cannabis. AMP will be purchasing and importing to Germany, 50 kilograms of EU-GMP medical cannabis in September 2020 and a further 100 kilograms during January/February 2021. AMP and the Canadian LP plan to expand the supply agreement for monthly large volume purchases of medical cannabis as well as extracts.

The Canadian LP operates an indoor growing and processing facility in Canada and was already EU-GMP certified by German authorities earlier this year.

Dr. Stefan Feuerstein, President of AMP, commented, "We are seeing a stronger than anticipated demand for medical cannabis in the German marketplace and Canada is one of a few credible suppliers to Germany in the short term. Demand from German pharmacies is so high that AMP will be adding pharmaceutical distributors across Germany that focuses solely on medical cannabis in the upcoming weeks. Our goal is to become a major importer to Germany by the end of 2021"

NATIONS Cannabis, an emerging Indigenous cannabis cultivation company and the Association of Canadian Cannabis Retailers (ACCRES) share a common vision for a regulated industry that ensures a safe supply and safe access to high quality products - and have formalized their alliance with the signing of a memorandum of understanding.

The MOU is the perfect marriage whereby NATIONS will provide a farm-to-store, steady supply of cannabis products for the 26 members of the Association, representing 65 retail stores. It also presents ACCRES with an opportunity to incorporate a truly Indigenous brand into its fold with an ability to cultivate new strains where market demands change. The projected value of the agreement is $28 million in the first year, and $96 million by year three.

"The partnership is pivotal in the evolution of NATIONS", says the company's co-founder and Executive Chairman, Wes Sam. "We are unaware of any such agreement involving an Indigenous production company in this province, and ACCRES has identified our company as the first it has chosen to collaborate with in this manner."

From the perspective of ACCRES, the deal is a win-win. "We believe NATIONS will become the premier and earliest Indigenous cannabis producer in BC, "said Association Interim President Mathew Greenwood. "They have a product that will allow our retailers to differentiate themselves from others in the marketplace. Furthermore, partnering with a company that gives an authentic voice to Indigenous Peoples is an important aspect of this collaboration and will be exciting for consumers."

As a late stage applicant in the federal licensing approval process, NATIONS' momentum was halted this spring amidst the COVID-19 pandemic and construction of its primary cultivation facility was paused. Once work resumes, the process of seeking and securing a federal cultivation and processing license will also continue.

"As investors in the NATIONS' project, we believe that the Agreement with ACCRES represents real Indigenous economic reconciliation and participation in the Cannabis industry," said Chief Dan George, of the Burns Lake Band (Ts'il Kaz Koh First Nation), adding, "We are excited to be part of this unique journey with NATIONS and their partners."

Upon licensing approval by Health Canada, NATIONS hopes to actively begin the process of facilitating a direct market arrangement with ACCRES and its respective retailers. Licensing approval will also open the door to a potential producer supply agreement through BC's Liquor Distribution Branch.

For more information about the Association of Canadian Cannabis Retailers, please visit:

For more information about NATIONS, please visit:

Investor ideas reminds all listeners to read our disclaimers and disclosures on the website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

Learn more about our cannabis podcasts at


Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

To hear more podcasts visit: podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About - News that Inspires Big Investing Ideas is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy:

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at

Follow us on Cannabis Social Media

Download our Mobile App for iPhone and Android



Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories

Buy a cannabis guest post on